Background: Gene associated with retinoid-interferon induced mortality-19 (GRIM-19) plays crucial roles in carcinogenesis. Objective: To explore the antitumor activity of internalizing NGR (iNGR) gene associated with GRIM-19 in colorectal cancer. Methods: Cells were incubated with fluorescein isothiocyanate-labeled fusion proteins followed by fluorescence microscopic analysis. Cell proliferation was determined by MTT assay. Cell cycle was analyzed by flow cytometric analysis. Cell migration and invasion capacity were evaluated by wound scratch and Transwell assays, respectively. Apoptosis was measured by Annexin V/PI staining and TUNEL assay. Gene expressions were determined by RT-PCR and Western blotting.
Introduction
Colorectal cancer is a highly prevalent malignancy in both men and women worldwide. In 2012, an estimated 1.4 million cases of colorectal cancer were diagnosed, and 693 900 cases of cancer-related mortality were attributed to colorectal cancer [1] . Surgery, chemotherapy, radiotherapy and multimodal approaches have been applied for the management of colorectal cancer [2] . The prognosis of this malignancy is closely associated with the tumor stage and therapy responses [2] . Emerging lines of evidence emphasize the promise of applying targeted therapy to the treatment of colorectal cancer [3] [4] [5] [6] .
Gene associated with retinoid-interferon induced mortality-19 (GRIM-19), a tumor suppressor gene, plays a crucial role in carcinogenesis of several human malignancies [7, 8] . Gene mutation and lossof-function of GRIM-19 has been noted in several tumor types [8] .
Regarding colorectal cancer, a recent study revealed that the GRIM-19 was downregulated in colorectal cancer tissues [9] . In addition, reduced GRIM expression is associated with the progression of colorectal cancer, with low level GRIM-19 expression related to poor differentiation and a more advanced stage of cancer [10] . Based on this evidence, it appears that overexpression of GRIM-19 might offer a novel therapeutic strategy for the management of colorectal cancer.
CD13, also known as aminopeptidase N (APN), is a membranebound protein overexpressed on the cell surface of several cancer cells [11] . A previous study indicated that CD13 is highly expressed in human colorectal cancer tissues [12] . NGR contains a Arg-GlyAsp motif that binds to APN and is homed to tumor cells [13, 14] . NGR serves as a targeting ligand and shows promise for use in the delivery of chemotherapeutic drugs. The internalizing NGR (iNGR) exhibits enhanced penetration of tumor vessels and tissues in addition to its CD13-targeting capability [15] . Therefore, we speculated that an iNGR-based drug delivery system could be applied to deliver the GRIM-19 gene to colorectal cells, where it would exert its antitumor activities.
For this purpose, in the present study, we constructed a iNGR-GRIM-19 fusion protein and tested its tumor targeting and tumor inhibition efficacies in vitro in cultured colorectal cancer cells as well as in vivo in xenografted nude mice. Our findings provide valuable insights for iNGR-GRIM-19-based targeted therapy for colorectal cancer.
Materials and methods

Expression and purification of iNGR-GRIM-19 fusion protein
GRIM-19 was synthesized according to the coding sequences (http:// www.ncbi.nlm.nih.gov/nuccore/NM_015965.6). The iNGR gene (TGCAGAAACGGACGGGGTCCAGATTGC) was synthesized and amplified by polymerase chain reaction (PCR) using primers synthesized by Shanghai GenePharma Co., Ltd. (China). After amplification, iNGR was ligated to the N-terminal domain of GRIM-19 to create iNGR-GRIM-19. After restriction enzyme digestion at the sites of BamHI and HindIII, the GRIM-19 and iNGR-GRIM-19 fragments were inserted into the pET32 a(+) vector (Novagen, Germany) to generate pET32a-GRIM-19 and pET32a-iNGR-GRIM-19, respectively, using a ClonExpress ® Entry One
Step Cloning Kit (Vazyme Biotech
Co., Ltd, Nanjing, China). The recombinant fusion protein was transformed into Escherichia coli BL21 (DE3) cells. Cells were grown in Luria broth (LB) medium containing 100 μg/ml ampicillin. Cells were lysed by sonication, and the fusion protein was extracted and used for PCR identification. The sequence of a product was further confirmed by DNA sequencing.
Preparation of fluorescein isothiocyanate (FITC)-labeled fusion protein
pET32a-GRIM-19 or pET32a-iNGR-GRIM-19 fusion protein was diluted to a working concentration of 0.2 mg/ml in phosphatebuffered solution (PBS; pH = 7.2) and incubated in carbonatebuffered dialysis solution (pH 9-9.5) overnight. The next day the fusion protein was mixed with FITC (Sigma-Aldrich, USA) at a ratio of 100: 1 (w/w), and the mixture was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 1 mg/ml. The FITC-labeled fusion proteins were dialyzed overnight in PBS. Membrane penetration capability of fusion protein
Colo205 and HCEpic cells were seeded onto glass coverslips placed in six-well plates at a density of 5 × 10 5 cells/well. The next day the culture medium was replaced with fresh medium supplemented with 40 μg/ml FITC-labeled fusion protein, and cells were incubated with fusion protein at 37°C for 2 h. After incubation, the culture medium was removed, and the cells were washed with PBS followed by methanol fixation. Nuclei were stained with DAPI (Sigma-Aldrich, USA) upon incubation with 1 μg/ml DAPI for 30 min at room temperature. After mounting in 50% glycerin diluted with PBS, samples were examined under a fluorescent microscope (Olympus, Japan) or laser scanning confocal microscope (Olympus, Japan).
Western blotting analysis
Total proteins were extracted from cell or tissue samples using radioimmunoprecipitation (RIPA) lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). After centrifugation at 12 000 r/min for 30 min at 4°C, the supernatant was collected and stored at −80°C until use. Bicinchoninic acid (BCA) assay was used for the measurement of protein concentration. Proteins were then separated by 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), transferred onto a polyvinylidene difluoride (PVDF) membrane, blocked in 5% non-fat milk solution, and incubated with primary antibodies at 4°C overnight. The primary antibodies used in this study were as follows: mouse anti-human monoclonal anti-GRIM-19 (1:1000), anti-Bcl-2 (1:1000), anti-survivin (1:500), anti-cleaved caspase-3 (1:1000), anti-cleaved caspase-8 (1:1000), anti-cleaved caspase-9 (1:1000), anti-vascular endothelial growth factor (VEGF; 1:1500), anti-matrix metalloproteinase-2 (MMP-2; 1:500), anti-MMP-9 (1:500), anti-cyclin-dependent kinase (CDK) 4 (1:1000), anti-cyclinD1 (1:1000) and anti-β-actin (1:1500) antibodies, all of which were purchased from Santa Cruz Biotechnology, USA. After washing, samples were probed with horseradish peroxidase (HRP)-labeled goat antimouse IgG secondary antibody (1:3000, Santa Cruz Biotechnology, USA), and the bands were visualized using an enhanced chemiluminescent (ECL) kit (Beyotime Institute of Biotechnology, Haimen, China). The densitometric values of the bands of interest were analyzed using a gel imaging system (Bio-Rad, USA) and Quantity One software, and relative protein expression was calculated upon normalization to the expression of β-actin.
Cell viability assay (MTT)
Cells were seeded onto 96-well plates at a density of 5000 cells/well. Twenty-four hours after the initial seeding, cells were incubated with 0, 5, 10, 20, 40, 60, or 80 μg/ml pET32a-iNGR-GRIM-19 or 60 μg/ml pET32a-GRIM-19 fusion protein for 24, 48, or 72 h. After incubation, 20 μl MTT solution (5 mg/ml) was added to each well. After 4 h of MTT treatment, the culture medium was removed, and 150 μl DMSO was added to each well. The absorbance of the dissolved product was measured at 490 nm using a microplate spectrophotometer (Molecular Devices, USA). Each treatment was repeated in five wells.
The growth inhibitory rate was calculated using the following equation: inhibition rate (%) = (1 -OD Sample /OD Control ) × 100%.
Colony formation assay
Cells were seeded onto 96-wells plates at a density of 5000 cells/ well. Twenty-four hours after initial seeding, cells were incubated with 20, 40, or 60 μg/ml pET32a-iNGR-GRIM-19 or 60 μg/ml pET32a-GRIM-19 fusion protein for 2 h at 37°C. After that, cells were collected and seeded onto 24-well plates at a density of 200 cells/well. After 7 days of incubation at 37°C, cultures were fixed in 3% glutaraldehyde for 10 min, and the number of colonies (≥50 cells) was counted. Each treatment was repeated in four wells. The colony formation rate and survival rate were calculated using the following formula: colony formation rate (%) = (number of colonies in sample group/200)/(number of colonies in control group/200) × 100%. Survival rate (%) = (colony formation rate in sample group/ colony formation rate in control group) × 100%.
Cell cycle analysis
Upon reaching 80% confluency, Colo205 cells were treated with 20, 40, or 60 μg/ml pET32a-iNGR-GRIM-19 or 60 μg/ml pET32a-GRIM-19 fusion protein for 48 h. Then, cells were collected, fixed with icecold 70% ethanol, and stained with propidium iodide (PI) solution containing RNase A for 30 min at 37°C in dark. Cell cycle was analyzed using a FACS Calibur Flow Cytometer (Becton Dickinson, USA) at a wavelength of 488 nm.
Cell apoptosis assays
Cell apoptosis was determined using Annexin V/PI double staining and TUNEL assay. In brief, after incubation with fusion protein for 48 h, cells were collected and resuspended in 100 μl Annexin V and PI solution (1:1; v/v). The percentage of apoptotic cells was measured using a FACS Calibur Flow Cytometer (Becton Dickinson, USA) at wavelengths of 488 nm and 518 nm. For TUNEL staining, cells were fixed in 4% paraformaldehyde (PFA) and permeablized with 0.1% Triton X-100. Endogenous peroxidase was inactivated by incubating the cells in 3% hydrogen peroxide for 10 min. After TUNEL staining for 90 min at 37°C in dark, samples were double stained with DAPI. The TUNEL-positive (apoptotic) cells were examined under a laser scanning confocal microscope (Olympus, Japan). Three fields were randomly selected for each sample, and the number of apoptotic cells was calculated over 200 cells.
Cell migration and invasion assays
Cell migration was evaluated using a scratch-wound assay. Briefly, cells were seeded onto six-well plates. Once cells reached 90% confluency, the cell monolayer was scratched by a 200-μl pipette tip. After washing with PBS, cells were exposed to culture medium containing fusion proteins for 48 h. The wound closure rate was calculated as follows: wound closure rate (%) = (scratched area before treatment -scratched area at 48 h after treatment)/scratched area before treatment × 100%.
The cell invasion capability was evaluated using a Transwell system. In brief, 2 × 10 5 Colo205 cells were seeded into the upper chamber of the Tranwell chamber (8-mm in diameter, Corning, USA) that was pre-coated with 80 μl of 200 μg/ml Matrigel. The chamber was then placed into a 24-well plates containing DMEM and 5% FBS. Cells were exposed to culture medium containing fusion protein for 48 h. After incubation, the cells and Matrigel in the upper chamber were scraped off with a cotton swab. The invading cells were fixed in methanol and stained with 0.5% crystal violet. Five fields were randomly selected under a phase contrast light microscope (Olympus, Japan), and the number of invading cells was counted.
RT-PCR
Total RNA, extracted from cells and tissues using Trizol reagent (Invitrogen, USA), was reverse transcribed into cDNA. After that, 2 μl cDNA template was mixed with 0.5 μl forward primer, 0.5 μl reverse primer, 12.5 μl 2 × SYBR Premix Ex Taq, and 9.5 μl distilled water and was amplified in a PCR detection system (Bio-Rad) with the following program: denaturation at 94°C for 30 s, annealing at 57°C for 30 s, and extension at 72°C for 45 s for a total of 30 cycles. The primers used for PCR amplification are listed in Supplementary  Table S1 . The relative mRNA expression level of each target gene was normalized to the expression level of β-actin.
Generation of xenografted nude mice bearing colorectal cancer and in vivo imaging
Six-to 8-week-old male BALB/c nude mice, weighing 20-25 g, were obtained from the Experimental Animal Center of Jilin University, China. Animals were maintained under a specific pathogen-free condition, with controlled temperature (23-25°C), humidity (50-60%), and lighting (12 h/12 h light/dark). All of the mice had free access to water and food.
To create the tumor-bearing mouse model, Colo205 cells were prepared as a single-cell suspension at a density of 1 × 10 8 cells/ml.
Then, 0.1 ml of the cell suspension was inoculated into the left flank of nude mice subcutaneously. When the size of the tumor mass was 100 mm 3 , mice were randomly divided into two groups (n = 4 per group), receiving 70 μg (4 mg/kg) FITC-labeled iNGR-GRIM-19 or GRIM-19 fusion protein by intraperitoneal injection. Two hours after injection, animals were placed into a small living animal imaging system (Kodak, USA) to visualize the location of the fusion protein.
Analysis of effects of 28-day treatment
Tumor-bearing nude mice were randomly divided into five groups (n = 16 mice per group) according to treatment with: vehicle, GRIM-19, low dose iNGR-GRIM-19, median dose iNGR-GRIM-19, and high dose iNGR-GRIM-19. In the GRIM-19 group, mice were given 16 mg/kg GRIM-19 by intraperitoneal injection every other day. In the iNGR-GRIM-19 treatment groups, animals were given 4, 8, or 16 mg/kg iNGR-GRIM-19 intraperitoneally every other day. In the vehicle control group, animals were injected with the same volume of PBS at the same frequency. The mouse body weight and tumor length and width were measured in six animals per group on days 0, 3, 7, 14, 21 and 28 after treatment. The tumor size was calculated using the equation [16] : tumor volume (mm 3 ) = length × (width) 2 × 0.52. The other 10 animals in each group were housed routinely, and animal survival time was recorded. After the 28-day therapy period, mice were anesthetized, and blood samples were collected by extirpating eyeballs. Blood samples were used for blood tests on a Coulter Hematology Blood Analyzer. The blood plasma was separated and used for examination of liver and kidney function indexes, including alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and creatinine (Cr) on a Synchron CX-9 Biochemistry Analyzer. Subsequently, the mice were killed, and the tumor mass, liver, kidney and bladder were removed. The tumor weight was measured. Samples were fixed for histological and TUNEL examination. Other tissue samples were 
Statistical analysis
Data were analyzed statistically using SPSS17.0 software and are expressed as means ± standard deviation (SD). Analysis of variance was applied to compare the differences between groups. Differences for which P < 0.05 were considered statistically significant.
Results
iNGR-GRIM-19 fusion protein penetrates the cell membrane
The iNGR-GRIM-19 and GRIM-19 recombinant proteins were prepared with a prokaryotic expression system and then purified. The sequences of the iNGR-GRIM-19 and GRIM-19 gene fragments were identified by PCR and DNA sequencing (Fig. 1A and data not  shown) . Western blotting analysis further confirmed the successful expression of the recombinant fusion proteins (Fig. 1B) .
We first examined the membrane penetration capability of the iNGR-GRIM-19 recombinant protein by incubating Colo205 colorectal cancer cells and normal control HCEpic cells with fusion protein for 2 h. As shown in Fig. 2A DAPI staining revealed that after membrane penetration, iNGR-GRIM-19 was localized both in the cytosol and nuclei of Colo205 cells (Fig. 2D) .
iNGR-GRIM-19 fusion protein inhibits proliferation and colony formation of colorectal cancer cell line
MTT analysis demonstrated that incubation with 60 μg/ml GRIM-19 for 24-72 h had no significant effect on the viability of Colo205 cells compared with that of the vehicle control (P > 0.05; Fig. 3A) . However, exposure to 0-80 μg/ml iNGR-GRIM-19 dose-and timedependently suppressed cell proliferation. The IC 50 values for iNGR-GRIM-19 in Colo205 cells were 38.4 ± 4.2, 23.7 ± 3.1 and 20.1 ± 2.7 μg/ml upon 24, 48, or 72 h of incubation. No significant difference was detected between the effects of the 48-h and 72-h incubation periods, or between the doses of 60 and 80 μg/ml (P > 0.05). Therefore, 48-h incubation was used in subsequent experiments. Morphological examination showed obvious inhibition of cell growth after incubation with 20-60 μg/ml iNGR-GRIM-19 for 48 h (Fig. 3B) . Moreover, exposure to iNGR-GRIM-19 at the concentration of 20 μg/ml greatly suppressed the colony formation and survival rate of Colo205 cells in a dose-dependent manner (P < 0.05 compared with vehicle or GRIM-19; Fig. 3C and D) .
iNGR-GRIM-19 fusion protein induces cell cycle G1 arrest in colorectal cancer cells
Flow cytometric analysis demonstrated that exposure to 20-60 μg/ml iNGR-GRIM-19 greatly increased the percentage of cells at G1 phase, compared to treatment with vehicle or GRIM-19, in a dose-dependent manner (P < 0.05; Fig. 4A and B) . Using PCR and Western blotting analyses, we found that 20-60 μg/ml iNGR-GRIM-19 dose-dependently downregulated the mRNA and protein expression of genes and proteins associated with the cell cycle, including CDK4 and cyclinD1, in Colo205 cells (Fig. 4C-F) . These data indicate that iNGR-GRIM-19 treatment induced G1 arrest in colorectal cancer cells.
iNGR-GRIM-19 fusion protein inhibits cell migration and invasion of colorectal cancer cells
To investigate the effects of the fusion proteins on the migration and invasion capacities of colorectal cancer cells, we performed a wound scratch assay and Transwell assay. As shown in Fig. 5A and B, 20-60 μg/ml iNGR-GRIM-19 dose-dependently inhibited the wound closure rate of Colo205 cells compared with the rates in the GRIM-19-or vehicle-treated groups (P < 0.05). Moreover, treatment with iNGR-GRIM-19 significantly suppressed the invasion of Colo205 cells across Matrigel (P < 0.01 compared to GRIM-19 or vehicle treatment; Fig. 5C and D) . The ability of iNGR-GRIM-19 to inhibit invasion appeared to be associated with its capacity to downregulate the VEGF, MMP-2 and MMP-9 genes in cells (Fig. 5E-H) .
iNGR-GRIM-19 fusion protein induces apoptosis in colorectal cancer cells
Using Annexin V/PI double staining, we found that treatment with 20-60 μg/ml iNGR-GRIM-19 dose-dependently increased the proportion of apoptotic cells in Colo205 cell cultures compared to treatment with 60 μg/ml GRIM-19 or vehicle control (P < 0.01; Fig. 6A and B) . Similar results were obtained for the TUNEL assay ( Fig. 6C and D) . In addition, compared to GRIM-19 or vehicle control, incubation with iNGR-GRIM-19 led to greatly upregulated mRNA and protein levels of cleaved caspase-3, -8, and -9, but downregulated expression of Bcl-2 and survivin ( Fig. 6E-H) .
iNGR-GRIM-19 fusion protein extends the lifespan of xenografted nude mice bearing colorectal cancer Table S2 ). Live imaging showed that the FITC-labeled iNGR-GRIM-19 fusion protein was localized specifically in tumor tissues (Fig. 7B) . Among tumor, liver and kidney tissues obtained from mice injected with iNGR-GRIM-19 or GRIM-19, fluorescence due to the FITC tag was detected only in tumor tissues of mice that received iNGR-GRIM-19 administration (Fig. 7C) . Western blotting analysis further confirmed the significant accumulation of GRIM-19 in tumor tissues treated with iNGR-GRIM-19 (P < 0.01 compared with that in tumor tissues treated with GRIM-19; Fig. 7D and E) .
iNGR-GRIM-19 fusion protein inhibits xenografted tumor growth and causes G1 arrest of colorectal cancer cells
Compared with the vehicle control and GRIM-19 treatment, administration of iNGR-GRIM-19 significantly reduced the tumor volume at 7 days after injection (P < 0.05; Fig. 8A ), but had no effect on animal body weight (P > 0.05; Fig. 8B ). After 4 weeks of therapy, iNGR-GRIM-19 at doses of 4, 8 and 16 mg/kg had reduced the tumor weight by 33.1%, 43.8% and 51.2%, respectively (inhibition rate of GRIM-19, 0.02%; Fig. 8C and D) . Flow cytometric analysis revealed that injection of iNGR-GRIM-19 resulted in an increased proportion of tumor cells at G1 phase (data not shown). Similar to the results of our in vitro study, iNGR-GRIM-19 injection decreased the expression of CDK4 and cyclinD1, in tumor tissues ( Fig. 8E-H) .
iNGR-GRIM-19 fusion protein induces cell apoptosis in xenografted colorectal cancer tissues TUNEL assay revealed that injection of iNGR-GRIM-19 fusion protein increased the number of apoptotic cells in tumor tissues in a dose-dependent manner, in comparison to vehicle or GRIM-19 injection (Fig. 9A ), but not in the liver or kidney tissues (data not shown). This finding was also confirmed by Annexin V/PI double staining (Fig. 9B) . In addition, the levels of cleaved caspase-3, -8 and -9 were upregulated, whereas the expression of Bcl-2 and survivin was downregulated by iNGR-GRIM-19 injection, as compared with vehicle or GRIM-19 injection (Fig. 9C-F) . Animal body weight after fusion protein or vehicle control injection. (C) Gross morphology and (D) average weight of tumor mass, n = 6 per group. The mRNA (E, G) and protein (F, H) expression levels of CDK4 and cyclin D1 were examined by PCR and Western blotting, respectively. The relative gene expression was normalized to that of an internal control. Data are expressed as mean ± SD, n = 6; **P < 0.01 versus vehicle and GRIM-19 treatment groups.
cells [15] . Multiple studies have successfully employed this system to deliver chemotherapeutic drugs (e.g. doxorubicin) [17] , small interference RNA (siRNA) [18] , PET-imaging probes ( 68 Ga) [19] , and nanocarriers [20] into diverse types of tumor cells. CD13 is highly expressed by human colorectal cancer cells [12] , raising the therapeutic potential of iNGR-based targeted therapy. CD13 is not only expressed in the angiogenic endothelium but also in other cell types. Several studies have shown that NGR selectively targeted CD13 in tumor blood vessels; while CD13 expressed in normal cells failed to bind to NGR [21, 22] . These findings have important implications in the development of vascular-targeted therapies based on the NGR/ CD13 system. HCEpic cell is widely-used intestinal control cell lines. Our preliminary experiment found that the expression of GRIM-19 was lower in Colo205 colorectal cancer cells than HCEpic cells (data not shown). It was reported that CD13 was highly expressed in Colo205 [12] . Therefore, we selected Colo205 and HCEpic cells to investigate the antitumor activity of iNGR-GRIM-19 fusion protein.
With construction of a fusion protein, we here for the first time report that the tumor suppressor gene GRIM-19, guided by iNGR, can be delivered specifically into Colo205 colorectal cancer cells, but not into HCEpic cells, which may reduce the side effects of targeted therapy. Moreover, after penetration, the fusion protein was found in both the cytoplasm and nuclei, suggesting the fusion protein might be internalized through an endosomal pathway. Consistent with our observations, localization of GRIM-19 of the cytoplasm and nuclei also was detected in human samples of non-small cell lung cancer [23] . The tumor mass-targeting of iNGR-GRIM-19 fusion protein was further confirmed in nude mice bearing Colo205 tumors. The results of in vivo imaging and immunofluorescence shows the iNGR-GRIM-19 fusion protein specifically binds to the CD13-expressing colon cancer through the ligand iNGR, and is not adsorbed by the normal tissue.
The in vitro antitumor capacity of iNGR-GRIM-19 fusion protein was examined in cultured Colo205 cells. Incubation with iNGR-GRIM-19 fusion protein for 2 h led to significant inhibition of cell proliferation and colony formation, and induced G1 phase arrest in cells. CDK4 and cyclin D1 cooperatively regulate the G1/S transition of the cell cycle [24] . A previous study showed that GRIM-19 induced G1 phase arrest in breast cancer cells by downregulating the expression of CDK4 and cyclin D1 [25] . In accordance with this finding, we also detected a dose-dependent reduction in CDK4 and cyclin D1 levels in response to incubation with iNGR-GRIM-19. iNGR-GRIM-19 fusion protein also inhibited the migration and invasion capability of Colo205 cells, which might be mediated through downregulation of the VEGF, MMP-2 and MMP-9 genes. Consistent with our results, it has been demonstrated that overexpression of GRIM-19 in SGC-7901 human gastric cancer [26] or MCF7 breast cancer [27] cells greatly reduces the levels of VEGF, MMP-2, and MMP-9, and thereby, inhibits the migration and invasion ability of cells. Furthermore, treatment with iNGR-GRIM-19 fusion protein led to apoptosis of Colo205 cells, as well as increased expression of the caspase cascades (cleaved caspase-3, -8 and -9) and decreased expression of anti-apoptotic genes Bcl-2 and survivin. Similar anti-apoptotic effects of GRIM-19 have been observed in hepatocellular carcinoma cells [28] . As GRIM-19 is identified as a subunit of mitochondrial complex I [29] , it is possible that upregulated expression of GRIM-19 may trigger mitochondria-dependent cell apoptosis.
The antitumor action of iNGR-GRIM-19 fusion protein also was tested in colorectal tumor-bearing nude mice. In addition to the growth inhibition, cell cycle arrest and apoptosis induction capabilities, iNGR-GRIM-19 was able to extend the lifespan of tumor-bearing nude mice, an effect which might be associated with its efficacy in inhibiting tumor growth and metastasis. However, the underlying mechanism of this process remains to be clarified. No obvious hematological, liver or kidney toxicity was observed upon iNGR-GRIM-19 administration, indicating the safety of this agent in the dose range of 4-16 mg/kg. However, we have not yet tested the long-term (28 days) therapeutic effects of this fusion protein.
Collectively, our current study provides valuable evidence illustrating the tumor targeting and antitumor activities of iNGR-GRIM-19 fusion protein for colorectal cancer. The use of iNGR-GRIM-19 fusion protein may be a novel strategy for the management of colorectal cancer.
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